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Hepatosplenic cat-scratch fever with seropositivity for 
Bartonella quintana?
In the Clinical Picture by Federico Laham and 
Sheldon Kaplan,1 we found an unexplained 
inconsistency between the clinical description of the 
case, which clearly could be related to a cat-scratch 
disease (history of cat scratch to the face), and the 
serological results, which are more indicative of a 
causative role for Bartonella quintana, instead of 
Bartonella henselae (antibody titres 1/32 768 and 
1/2048, respectively). B henselae is transmitted by cat 
scratch and causes a regional lymphadenitis, whereas 
B quintana, transmitted by body louse bites, was 
responsible for the “classic“ trench fever (especially 
during World Wars I and II). At present, B quintana is 
related to chronic lymphadenopathy, bacteraemia, 
endocarditis, bacillary angiomatosis, and peliosis in 
patients with advanced HIV infection, and bacteraemia, 
with and without endocarditis, in homeless people 
without HIV infection, most notably in Seattle, WA, 
USA, and Marseille, France.2,3
In a case clinically similar to that described by Laham 
and Kaplan—ie, an immunocompetent man with a 
3-day history of progressive right retromandibular 
swelling—but without fever and weight loss or other 
symptoms and signs, and without history of cat contact 
or cat scratch, we isolated a B quintana strain from the 
enlarged parotid gland of the patient (Mansueto P et al, 
unpublished data). Serology was negative for B henselae 
and positive for B quintana (IgG 1/256 [normal less 
than 1/64] and IgM 1/40 [normal less than 1/20], 
respectively).
In the case report from Seattle,2 B quintana was isolated 
from the blood specimens of ten homeless patients 
with fever and persistent bacteraemia: three patients 
reported a recent cat scratch, ﬁ ve had scabies, and one 
had body lice. Perhaps Bartonella spp have many things 
still to tell.
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